Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

This expert-led discussion captures proceedings from one of a series of visiting professorship programs to support specialists in the introduction of recently approved and emerging antibody drug conjugates to address unmet needs in the treatment of metastatic TNBC. This activity also includes patient cases that incorporate the latest evidence. Excerpts from the live Q&A session and downloadable TNBC resources are also provided.

Topic Highlights:

• TNBC treatment challenges

• ADC mechanistic rationale

• Role of TROP2 in TNBC

• Case-based application of current data and recommendations

Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

Expert Perspectives

Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC.

What are the latest data with these ADCs? Why is TROP2 an effective target in TNBC? How do we best incorporate these TROP2-targeted ADCs into TNBC care? This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment. This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC.

Updates:

August 5, 2022: Fam-trastuzumab-deruxtecan-nxki is now approved to treat patients with unresectable or metastatic HER2-low breast cancer

Faculty: Sara Hurvitz, MD, FACP

Release Date: December 23, 2021

Expiration Date: December 23, 2022

CME/CE is no longer available for this activity